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Recent studies have established the role of rare copy number variants (CNVs) in several 
neurological disorders but the contribution of rare CNVs to cerebral palsy (CP) is not 
known. Fifty Caucasian families having children with CP were studied using two 
microarray designs. Potentially pathogenic, rare (<1% population frequency) CNVs 
were identified, and their frequency determined, by comparing the CNVs found in cases 
with 8,329 adult controls with no known neurological disorders. Ten of the 50 cases 
(20%) had rare CNVs of potential relevance to CP; there were a total of 14 CNVs, 
which were observed in <0.1% (<8/8,329) of the control population.  Eight inherited 
from an unaffected mother: a 751 kb deletion including FSCB, a 1.5 Mb duplication of 
7q21.13, a 534 kb duplication of 15q11.2, a 446 kb duplication including CTNND2, a 
219 kb duplication including MCPH1, a 169 kb duplication of 22q13.33, a 64 kb 
duplication of MC2R, and a 135 bp exonic deletion of SLC06A1.  Three inherited from 
an unaffected father: a 386 kb deletion of 12p12.2-p12.1, a 234 kb duplication of 
10q26.13 and a 4 kb exonic deletion of COPS3.  The inheritance was unknown for three 
CNVs: a 157 bp exonic deletion of ACOX1, a 693 kb duplication of 17q25.3 and a 265 
kb duplication of DAAM1. This is the first systematic study of CNVs in CP and 
although it did not identify de novo mutations, has shown inherited, rare CNVs 







Cerebral palsy (CP) is the most common motor disorder of childhood, with a prevalence 
of 2-2.5/1,000 live births.1, 2  Cerebral palsy has been defined as “a group of permanent 
disorders of the development of movement and posture, causing activity limitation, that 
are attributed to non-progressive disturbances that occurred in the developing fetal or 
infant brain.  The motor disorders of cerebral palsy are often accompanied by 
disturbances of sensation, perception, cognition, communication, and behaviour, by 
intellectual disability, autism and epilepsy, and by secondary musculoskeletal 
problems”.3  Evidence of intrapartum fetal compromise is found at birth in less than 
10% of cases.4  There are a number of known major epidemiological risk factors for CP, 
including preterm delivery, intrauterine growth restriction (IUGR), intrauterine infection 
and multiple pregnancy.5   
There is evidence of genetic susceptibility to CP but little is known about 
possible mechanisms.6  Monozygotic twins have a significantly higher (p = 0.0026) 
concordance rate for CP compared to dizygotic twins.7  Several family studies have 
determined the likely inheritance pattern responsible for different clinical manifestations 
of CP.8, 9  SNP association studies have been reported but have provided inconclusive 
results because of small sample sizes.10 
A genetic linkage study mapped an autosomal recessive type of spastic CP to a 
locus on chromosome 2p24-2511 and subsequently, a missense variant was found in the 
GAD1 gene, which segregated with the CP phenotype (LOD score 5.75).12  However, 
the functional effect of this variant was not assessed and no GAD1 variants have since 




affecting four children from a complex consanguineous family was mapped to 
chromosome 9p12-q12 (LOD score 3.4).13 
More recently, mutations in all four subunits of the adaptor protein complex-4 
(AP4E1, AP4M1, AP4B1, and AP4S1) were reported to cause a CP-like motor 
disorder.14-17  The phenotype of the affected individuals included slowly progressive 
spasticity and therefore does not fit the classical definition of CP, which assumes non-
progression. A very slowly progressive neurological disorder may be classified as CP at 
one point in time, with the need to change the diagnosis after a longer period of 
observation.18  It is now clear that de novo and inherited copy number variants (CNVs) 
contribute to the aetiology of various neurological disorders such as autism,19 
intellectual disability,20, 21 and epilepsy.22  The extent to which this is based on single 
‘hits’ of large effect, or two or more hits of smaller effect acting synergistically, is 
uncertain.20, 23  The contribution of CNVs to CP has not yet been systematically 
investigated; this work addresses this knowledge gap by testing a selected cohort of 50 





DNA samples and study cohort  
To determine whether rare CNVs (<1% population frequency) contribute to CP 
causation, we used two separate custom microarrays to study DNA samples from 50 
Caucasian children with a diagnosis of CP confirmed by a specialist. All cases were 
identified from the South Australia CP Register and recruited through paediatric 
rehabilitation specialists at the Women’s and Children’s Hospital, Adelaide.18  Parents 
were tested when potentially relevant CNVs were found and parental samples were 
available.  No other selection criteria were applied.  Clinical data were collected for 
each case, including gender, details of pregnancy and birth, gestational age, Apgar 
scores, birth weight and head circumference, and neonatal events.  Also collected, were 
type of CP and co-morbidities such as intellectual disability, autism, and epilepsy.  
Growth restriction was assessed using a customised birth weight centile program.24  
Results were compared to 8,329 samples from adults with no known 
neurological disorders.21  This control dataset has been described previously in detail.21  
Results were also compared with the frequency of events in 337 National Institute of 
Mental Health (NIMH) controls analysed using the same 135K array.25 
DNA isolated from lymphoblastoid cell lines was used for CNV analyses, and 
DNA isolated from whole blood was used for subsequent CNV validations.  Parental 
DNA was isolated from whole blood only.  Signed parental consent and ethics approval 
from the Adelaide Women’s and Children’s Health Network Human Research Ethics 







Two customised microarray platforms were used.  The first was a customised 180K 
chromosomal microarray with targeted plus whole genome coverage (Agilent 
Technologies, CA, US).  The targeted coverage included clinically relevant regions such 
as known deletion/duplication syndrome regions, telomeres and centromeres at a 
resolution of ~20-50 kb plus exon-level coverage of >1200 genes involved in 
neurodevelopmental disorders.  The whole-genome backbone results in a resolution in 
unique DNA of ~225 kb.  Feature Extraction (version 10.5.1.1) and DNA Analytics 
(Version 4.0.81) software (Agilent Technologies) was used to perform data analysis. 
The second array platform was a customised 135K microarray (Roche 
NimbleGen, Madison, WI, US), with one probe every 2.5 kb in the genomic hotspots 
(regions flanked by segmental duplications) and 35 kb density in the genomic backbone.  
All microarray hybridization experiments were performed as described previously,26 
using a single unaffected male (GM15724 from Coriell) as reference.  The empirically 
determined detection resolution for this array was >50 kb within the hotspots and > 350 
kb in the genomic backbone.25  All microarrays were analysed by mapping probe 
coordinates to the human genome assembly Build 36 (hg18).  To minimise false 
positives on both array platforms, deletions and duplications were determined by a 
minimum of four consecutive probes beyond a mean significance Log 2 ratio of -0.26 
and 0.3 respectively.  All CNV calls were manually inspected by loading the signal 
intensity data onto a custom University of California Santa Cruz (UCSC) browser.  
CNV regions of interest identified in CP cases and their parents, were validated by 





Clinical details of cases with rare CNVs 
We studied 50 cases of CP, all born to non-consanguineous parents of Caucasian 
(northern European) descent.  There were 28 males and 22 females.  Twenty-four 
(48%) were born at term, and the remaining 26 (52%) were born at <37 weeks 
gestation.  The mean birth weight was 2352 g (680–4650 g).  One out of the 50 cases 
(2%) had documented intrauterine growth restriction.  Spastic hemiplegia was the 
most prevalent type of CP with 22 cases (44%), followed by diplegia with 13 cases 
(26%), quadriplegia with 13 cases (26%), and triplegia with 2 cases (4%).  The gross 
motor function classification system (GMFCS) was used to measure severity:  level 1 
which indicated independent walking through to level 5 where the individual is 
wheelchair dependent.27  Twelve cases (24%) were documented at level 1, 8 cases 
(16%) at level 2, 4 cases (8%) at level 3, 5 cases (10%) at level 4, 8 cases (16%) at 
level 5 and for 13 cases GMFCS was not documented. Sixteen cases (32%) had 
intellectual disability, 16 cases (32%) had epilepsy, and autism was reported in 5 
cases (10%).  The mean maternal and paternal ages were 30 years (22–42 years) and 
32 years (23–47 years), respectively  (Supplementary Table 2). 
 
CNV burden in cerebral palsy 
We assessed the total CNV load in individuals with CP (n=50) compared to those from 
previously published CNV data on autism (n = 350), intellectual disability (n=501), and 
controls from the NIMH cohort.25  Notably, all these CNVs were discovered using the 
same array design facilitating comparison across disease cohorts.  CNV load in CP was 




Rare CNV discovery and validation 
For rare CNV detection, we utilized CNV calls from both array platforms (see 
methods).  Eighty-four variants were identified by using both arrays, therefore 
considered validated.  Based on comparison to CNV calls from population controls 
these CNVs were classified as rare, potentially pathogenic events, benign, or common 
variants (>1% population frequency) (Supplementary Table 3). 
Fourteen different rare (observed in <0.1% [<8/8,329] of the control 
population) potentially pathogenic, CNVs, were found in 10 out of the 50 cases 
(20%) were studied.21  Their mean genomic size was 355 kb (range 135 bp to 1.5 
Mb).  There were five (36%) deletions with mean size 228 kb (135 bp to 741 kb) and 
nine (64%) duplications with mean size of 466 kb (65 kb to 1.5 Mb).  None of these 
rare potentially pathogenic variants were observed among the NIMH controls, but the 
small sample sizes precludes statistical rigor (Table 1). 
Eight of the 14 CNVs were maternally inherited.  Five involved single genes: 
a 751 kb deletion involving the entire FSCB gene, a 446 kb duplication which 
included the first exon of CTNND2, a 219 kb duplication involving the first exon of 
MCPH1, and a 64 kb duplication involving the entire MC2R gene and a 135 bp 
exonic deletion involving SLC06A1.  The other three maternally inherited CNVs 
contained several genes each: a 1.5 Mb duplication of 7q21.13 (ZNF804B, 
MGC26647, STEAP1, STEAP2, FLJ21062), a 535 kb duplication of 15q11.2 
(TUBGCP5, CYFIP1, NIPA2, NIPA1), and a169 kb duplication of 22q13.33 (SAPS2, 
SBF1, ADM2, MIOX, LMF2, NCAPH2, SCO2, TYMP, LOC440836).  Three of the 14 
CNVs were paternally inherited.  One involved a single gene; a 4 kb deletion 




contained several genes each: a 387 kb deletion on 12p12.2-p12.1 (SLCO1B3, LST-
3TM12, SLCO1B1) and a 234 kb duplication of 10q26.13 (METTL10, KIAA0157, 
ZRANB1, CTBP2).  Of these eleven CNVs, two (12p12.2-p12.1 and COPS3) were 
inherited from father to daughter and six (MCPH1, FSCB, MC2R, SLCO6A1, 15q11.2 
and 22q13.33) were inherited from mother to son.  We could not determine whether 
the remaining three CNVs were inherited or de novo due to the unavailability of 
parental DNA.  These included two single-gene CNVs: a 157 bp exonic deletion of 
ACOX1 and a 265 kb duplication of exons 1-4 of DAAM1, and one CNV containing 
several genes: a 693 kb duplication of 17q25.3 (HRNBP3, ENPP7, CBX2, CBX8).  
Five of the 14 CNVs were identified by both arrays, nine were found on the 180K 
array only as the 135K array did not have sufficient probe coverage for these regions.  
Each of these fourteen CNVs was validated by qPCR (Table 1). 
Several of these CNVs involve known OMIM (Online Mendelian Inheritance 
in Man) genes.  These included CTNND2 (OMIM 604275), MCPH1 (OMIM 607117, 
251200), NIPA2 (OMIM 608146), NIPA1 (OMIM 608145), ACOX1 (OMIM 264470) 
and MC2R (OMIM 607397).  Four of these genes are also reported in Decipher as 
having a predicted likelihood of haploinsufficiency (HI): CTNND2 (26.1%), NIPA1 






This is the first study to assess the potential contribution of CNVs to the aetiology of 
CP.  Two different customised, microarray platforms were utilized to maximize CNV 
detection in this cohort.  Both platforms had been designed and validated for clinical 
testing of disorders found in high prevalence in the population including intellectual 
disability, autism, and epilepsy, disorders that are common co-morbidities of CP.  We 
identified 14 CNVs that are plausible contributors to the aetiology of CP in 10 of 50 
(20%) affected individuals.  All are rare (<1% population frequency).  Ten of the 14 
CNVs were larger than 150 kb.  Five of the 14 CNVs were deletions with an average 
size of 228 kb and one of them involved a gene, COPS3 that is predicted to be dosage 
sensitive.  Nine of the 14 CNVs were duplications with an average size of 466 kb (the 
largest spanning 1.5 Mb), and three involved genes (CTNND2, NIPA1 and DAAM1) 
that are predicted to be dosage sensitive. 
All 14 CNVs involve genes expressed in the brain, several of which have been 
reported to participate in the pathogenesis of other neurological disorders.  These 
include:  i) ACOX1 157 bp exonic deletion found in case P023.  ACOX1 is the first 
enzyme in the peroxisomal β-oxidation very-long-chain fatty acids.  Autosomal 
recessive mutations in ACOX1 cause peroxisomal acyl-CoA oxidase deficiency 
(OMIM 264470) and involve the nervous system.  Clinical phenotypes with ACOX1 
deficiency include white matter abnormalities, early onset hypotonia, neonatal seizures 
and psychomotor delay.28  ii) A small 4kb deletion of exons 4 - 6 of COPS3 in case 
P020.  COPS3 is one of eight subunits of the COP9 signalosome protein complex and 
is involved in a variety of cellular and developmental processes and in signal 




COP9 can destabilize the structure of the entire complex.30  COPS3 maps to 
chromosome 17p11.2, within the Smith-Magenis Syndrome (SMS) and Potocki-Lupski 
Syndrome (PTLS) critical interval.31 32  Autism spectrum disorder, the main feature of 
PTLS, has been reported in approximately 80% of cases.33  As with SMS, PTLS is also 
characterised by congenital abnormalities and intellectual disability.33  iii) A 534 kb 
duplication on 15q11.2 found in case P025 includes four highly conserved genes: 
TUBGCP5, CYFIP1, NIPA2 and NIPA1.  TUBGCP5 is expressed in the subthalamic 
nuclei and CYFIP1 is widely expressed in the central nervous system.  Deletions of 
15q11.2 map to the critical region of the Prader-Willi syndrome/Angelman syndrome34 
(OMIM 608145, 608146).  Microdeletions of 15q11.2 region have also been reported 
in cases with delayed motor and speech development, autism, obsessive-compulsive 
disorder and dysmorphic features without Prader-Willi/Angelman syndrome, 
suggesting haploinsufficiency for TUBGCP5, CYFIP1, NIPA2 and NIPA1.35  While 
observed in control individuals, the role of 15q11.2 duplications is yet to be unravelled.  
iv) CTNND2 446 bp duplication in case P036. CTNND2 is highly expressed in fetal 
brain and plays an important role in neuronal functioning, adhesion, and migration.36, 
37
.  It is involved in early embryogenesis and encodes an adhesive junction associated 
protein of the armadillo/beta-catenin superfamily. 38  CTNND2 has been associated 
with intellectual disability in cri-du-chat syndrome36 (OMIM 604275), autism when 
deleted, 38, 39 and schizophrenia when duplicated.37  Previous studies have reported 
both dosage variation and disruptive effects resulting from CNVs involving 
CTNND2.37, 40  This gene has a predicted HI of 26.1%.  v) A 219 bp duplication in case 
P025 involving exon 1 of MCPH1.  Microcephalin, the product of MCPH1, highly 




cerebral cortex size.  Homozygous loss of function mutations of the MCPH1 gene 
(OMIM 607117, 606858 and 251200) cause autosomal recessive disorders including 
premature chromosome condensation syndrome,42 intellectual disability,42 and 
microcephaly.43  Heterozygous deletions and duplications of MCPH1 have been 
reported in families with autism spectrum disorders, supporting the concept that 
MCPH1 is a dosage sensitive gene, with considerable mutation pleiotropy.44  vi) A 64 
kb duplication of MC2R identified in case P053.  MC2R can result in the rare 
autosomal recessive disorder, familial glucocorticoid deficiency.  Clinical 
characteristics related to hypoglycaemia can include hypertonic seizures, skin 
hyperpigmentation and muscle weakness.45 
Eleven of the 14 CNVs that we identified were inherited from an unaffected 
parent and were considered to be of potential relevance to CP.  Reasons for 
discordance between parent and child could include variable expressivity,46 incomplete 
penetrance,47 and epigenetic modification of gene expression.47  Expression of a 
clinical phenotype in the child but not in the parent could also be explained by the ‘two 
hit’ hypothesis,20, 23 which postulates the additive effects of two or more de novo or 
inherited genetic abnormalities in the affected individual, with fewer such 
abnormalities in the unaffected parent.  Other mechanisms include the presence of a 
point mutation on the other allele in the affected children, not identified by the CNV 
profiling,48 and various combinations of CNVs and point mutations affecting different 
genes.23  Genetic susceptibility may also be triggered by environmental risk factors for 
CP such as prematurity and IUGR.5 
In some cases, it will be the combination of genetic and non-genetic risk factors 




and two of these carried two or more CNVs.  Another case, born at term, carried two 
maternally inherited CNVs: including a 535 kb duplication of 15q11.2 and a 219 kb 
duplication of MCPH1.  Homozygous mutations involving MCPH1 are known to 
cause autosomal recessive primary microcephaly.  In this case microcephaly was 
absent, head circumference was normal at birth (35 cm) and again at seven months age 
(45 cm). Magnetic resonance imaging showed left porencephaly following 
periventricular leukomalacia, which would be atypical of microcephaly. Sequencing of 
the other MCPH1 allele showed no other variant (unpublished data).  Another case was 
born following an emergency caesarean section, performed because of non-reassuring 
fetal condition and diagnosed with IUGR and hypothyroidism.  However, there did not 
appear to be a difference in perinatal risk factors between the 10 cases with CNVs and 
the other 40 cases in the cohort.  Type and severity of CP and other comorbidities were 
also similar between these two groups. 
The strengths of this initial study are the use of two array platforms, the design 
and criteria for CNV calling, the rigorous validation and the plausible role these 
individual CNVs might play in disrupting various neurodevelopmental pathways.   
The weaknesses of this study are that no de novo CNVs were found and it 
remains to be determined whether the inherited CNVs described led to a CP phenotype 
due to co-genetic or environmental triggers.  The small sample size and the inherited 
nature of the CNVs make it is difficult to determine their true pathogenicity.  The cases 
collected for this study were by necessity from a heterogeneous group of volunteer 
families which was generally representative of the CP population in terms of 
gestational age, risk factors for CP, and CP subtype.  No exclusions were made on the 




may be involved in plausible biological pathways, one of the two arrays was 
intentionally targeted at genes known to be involved in neurodevelopmental disorders.  
This potential bias was offset by the rarity of these events in the control population.  
Nevertheless their precise contribution to CP requires much more investigation. 
Not all parents were tested and of the cases whose parents were tested, no de 
novo CNVs were identified at the resolution of the 180K array (20-50 kb targeted 
regions, 225 genomic backbone) and the 135K array (>50 kb hotspot region, >50 kb 
genomic backbone). An increased CNV burden was not observed compared to the 
NIMH control cohort.  This may reflect the lack of statistical power in detecting rare 
events in this cohort, or could be due to the fact that both array platforms were 
underpowered for detecting genome-wide small CNVs.  Therefore, the true CNV 
contribution to CP may be underestimated.  There was potential bias in our study 
cohort with regards to subtype and severity of CP.  Only thirteen out of 50 cases (26%) 
had a GMFCS score of ≥4.  It is possible that de novo pathogenic CNVs will have an 
increased yield in individuals with more severe CP subtypes. We identified 10 out of 
50 cases with one or more potentially pathogenic CNVs for CP. Where parental DNA 
was available, 11 out of 14 CNVs were found to be inherited from an unaffected 
parent, suggesting a more complex genetic aetiology than a major causative effect.  
The contribution of other genetic or environmental factors to CP in this cohort was not 
investigated.  Genome/exome sequencing has the potential to identify further sequence 
variation which likely contributes to CP and was not evaluated in this study.  
Evaluation of the contribution of CNVs to CP awaits further confirmation in a larger 
independent cohort.  However, these data suggest that in this cohort CNVs may 
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Figure 1  CNV burden analysis for cerebral palsy. 
The figure shows the population frequency of the largest CNV (as a survivor funtion) in 
individuals with cerebral palsy compared to 337 controls from the NIMH cohort and as  
a comparison of CNV burden to CNV data from individuals with intellectual disability, 
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F 32 30 Dip 
P011 14q23.1 Chr14:58,593,026-58,804,264 265,283 dup DAAM1 unknown no yes 0 0 F 30 28 Dip 
P013 17q25.3 Chr17:74,722,430-75,415,451 693,021 dup HRNBP3, ENPP7, CBX2, 
CBX2, CBX8 
unknown yes yes 0 NA F 40 U Hem 
P017 14q21.3 - Chr14:43,617,568-44,369,205 751,637 del FSCB maternal yes yes 1 0 M 39 U Quad 
P020 17p11.2 Chr17:17,104,399-17,108,906 4,507 del COPS3 intragenic paternal no yes NA NA F 40 U Hem 
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M 40 35 Hem 



















MC2R entire gene 
SAPS2, SBF1, ADM2, 
MIOX, LMF2, NCAPH2,  























M 36 35 Quad 
P057 10q26.13 Chr10:126,466,575-126,700,900 234,325 dup METTL10, KIAA0157, 
ZRANB1, CTBP2 
paternal no yes 0 NA M 29 U Hem 
 
*8,329 adult controls with no known neurological disorders;  $NIMH (National Institute of Mental Health);  NA - denotes no data on controls due to low probe coverage, HC – head circumference, U – no 
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